GlobeNewswire Inc.··Medicinova, Inc.MediciNova Completes Phase 2 Trial of Tipelukast for Metabolic Disease
MediciNova completes Phase 2 trial of tipelukast for metabolic disease; top-line data expected Q3 2026.
MNOVPhase 2 clinical trialType 2 diabetes